Business
Publication highlights potential of SCIB1 therapy
Publication highlights potential of SCIB1 therapy.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5035E Scancell Holdings Plc 12 February 2018 \n\n12 February 2018\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \n \nPeer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients\n \nCompelling 5-year survival data with most resected stage III and IV patients remaining alive \n \nPhase 2 trial anticipated to start in H2 2018\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of a peer-reviewed research paper in the scientific journal OncoImmunology entitled: \"Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a Phase 1/2 trial\". The Company also provides an update on current survival data along with its future plans for a US clinical trial in patients with malignant melanoma. \n \nThe publication describes the outcome of the Company's Phase 1/2 clinical trial of SCIB1 in patients with malignant melanoma up to the date when all patients had received five doses of SCIB1 in the main part of the study. The paper concludes that \"SCIB1 is a novel class of anti-cancer immunotherapy that induces T cells which can cause tumour regression in patients with melanoma. The high frequency of responses, their breadth and durability suggest that SCIB1 is worthy of further study in a larger cohort of patients. This is particularly the case in the adjuvant setting, where all of the patients responded immunologically and where absence of toxicity is an important clinical consideration. Furthermore, the stimulation of potent de novo immune responses by SCIB1 may provide an opportunity for synergistic combination therapy with checkpoint inhibitors in late stage disease.\" The full abstract of the paper can be found below.\n \nSCIB1 ongoing survival data\n \nSince the cut-off date for the publication, the Company has continued to collect survival data for the trial patients and, as of February 2018, SCIB1 continues to deliver increasingly impressive results:\n \n· Over...